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In the past two decades, thanks to eﬀ ective 
antiretroviral treatment (ART), enormous progress has 
been made in improving the health and life expectancy 
of HIV-infected individuals.1 The success of ART, 
combined with the beneﬁ ts of treatment as prevention 
and pre-exposure prophylaxis on HIV transmission, have 
generated new hope to end the HIV/AIDS epidemics.2 
Translation of this hope into universal reality will need 
accelerated eﬀ orts to ensure rapid access to ART and 
to extend HIV prevention services to reach the most 
aﬀ ected populations and regions. These advances will 
only be feasible with an accurate and detailed picture 
of the HIV pandemic, and especially of the trends in 
HIV incidence—one of the most crucial epidemiological 
indicators and the most challenging to estimate.3
For many years, global estimates of the HIV burden 
have been produced by UNAIDS only, and have been 
largely based on HIV prevalence data and complex 
mathematical models.4 In 2014, Christopher Murray 
and colleagues5 provided an alternative assessment 
of HIV incidence, prevalence, and mortality for the 
Global Burden of Disease Study (GBD) 2013. The 
investigators used complex mathematical models 
and speciﬁ ed underlying assumptions to estimate HIV 
incidence and prevalence in each country, mainly from 
the number of deaths caused by HIV recorded in vital 
registration systems. In The Lancet HIV, Haidong Wang 
and colleagues6 have reﬁ ned this methodology and 
data sources, and present updated estimates of HIV 
mortality, prevalence, and incidence from 1980 to 2015 
at the global, regional, and national level. The GBD 
2015 Study is far more than an update; it oﬀ ers an 
opportunity to discuss several important issues about 
what remains to be done to track HIV epidemics.
First, health estimates are subject to substantial 
revision.3 Wang and colleagues estimate that 
38·8 million people (95% uncertainty interval [UI] 
37·6–40·4 million) were living with HIV in 2015, an 
increase of almost 10 million compared with the GBD 
2013 estimate of 29·2 million (28·1–31·7 million). The 
investigators also estimate that 2·5 million people 
(95% UI 2·2–2·7 million) were newly infected with HIV 
in 2015, an increase of 40% compared with the 2013 
estimate of 1·8 million (1·7–2·1 million). Notably, in 
2007, UNAIDS revised downwards the estimates of 
people living with HIV from 39·5 million to 33·2 million, 
and HIV incidence from 4·3 million to 2·5 million.3 These 
revisions result from improvements in data sources and 
estimation methods, and do not reﬂ ect real changes 
in the HIV epidemics, but they also suggest that a 
degree of caution is warranted in interpretion of the 
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Newly diagnosed HIV cases in 
2014
GBD estimates of the number of new 
HIV infections in 2015 (95% UI)6
Russia15 85 252 57 340 (32 750–102 270)
USA11* 44 073 23 040 (17 680–29 960)
Ukraine10 15 796 13 490 (9920–18 670)
France14* 6584 960 (360–2040)
UK10* 6141 2060 (1660–2540)
Italy10 3695 1960 (760–4190)
Germany10 3525 1760 (650–3660)
Spain10 3366 2350 (990–4760)
Kazakhstan10 2350 1630 (880–2640)
Canada12 2090† 1110 (180–2810)
Turkey10 1812 720 (280–1280) 
Belarus10 1811 1370 (760–2290)
Australia13* 1333 390 (150–840)
Poland10* 1061 410 (130–670)
Belgium10* 1039 210 (60–470)
Tajikistan10* 985 320 (140–610)
Portugal10 920 2220 (530–4910)
Netherlands10* 831 200 (70–470)
Moldova10 831 540 (310–920)
Romania10* 791 450 (150–690)
Greece10* 714 50 (30–90)
Kyrgyzstan10* 645 320 (160–620)
Azerbaijan10* 604 360 (170–580)
Georgia10* 536 150 (80–250)
Switzerland10* 515 200 (50–450)
Israel10* 477 170 (50–350)
Ireland10* 359 60 (10–140)
Sweden10* 350 80 (30–150)
Latvia10 347 170 (50–350)
Armenia10* 332 70 (30–130)
Estonia10* 291 110 (60–190)
Hungary10* 271 60 (40–80)
Norway10* 268 50 (20–110)
Denmark10 256 130 (30–300)
Bulgaria10 247 140 (60–260)
Austria10 235 310 (100–710)
Czech Republic10* 232 40 (10–70)
Finland10* 181 30 (10–80)
Countries are ranked according to the reported number of newly diagnosed HIV cases. GBD=Global Burden of Disease. 
UI=uncertainty interval. *Countries in which the GBD uncertainty intervals do not include the value of the reported 
number of newly diagnosed HIV cases. †Number of newly diagnosed HIV cases in 2013.
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results from these global approaches. Previously, the 
GDB 2013 Study concluded that the HIV epidemic was 
much smaller than previously thought—a diﬀ erence of 
6 million was found between the GBD 2013 and UNAIDS 
2013 estimates of HIV prevalence, with no overlap in the 
uncertainty intervals.5 In the present update, the number 
of people living with HIV in 2015 was slightly, albeit not 
signiﬁ cantly, higher in GBD estimates for 2015, than 
in UNAIDS estimates for 2015 (36·7 million, 95% UI 
34·0–39·8 million).7 The similarity in the estimates for 
overall HIV prevalence in 2015 hides some important 
diﬀ erences between them for most regions of the world. 
These diﬀ erences need further investigation.
The second issue is can we infer recent trends in 
incidence from the number of deaths due to the disease 
of interest? For HIV, the answer is no. There is a prolonged 
time lag between infection with HIV and death caused 
by HIV (on average 11 years without treatment8 and 
much longer with treatment1). This lag means that the 
number of HIV deaths could, at best, provide information 
about trends in HIV incidence a decade ago, but not 
about recent trends. Furthermore, with increased access 
to multiple classes and lines of highly eﬀ ective ART, 
mortality directly related to HIV will hopefully become 
rare, as is already the case in most high-income countries, 
and thus use of trends in HIV mortality to inform trends 
in HIV incidence will prove ineﬀ ective. We,9 and others,4 
have already drawn attention to this issue and showed 
that the GBD estimates of HIV incidence for the regions 
of North America, Europe, central Asia, and Australasia 
were highly unrealistic. Not surprisingly, the issue 
remains present in Wang and colleagues’ update, because 
the main changes introduced in the 2015 study did not 
include changes to the methods used for these regions. 
The GBD estimates of HIV incidence are signiﬁ cantly 
lower (two to ten times) than the reported number of 
newly diagnosed HIV cases for most countries in these 
regions (table), while the number of new HIV infections 
is expected to be close to or greater than the reported 
number of newly diagnosed HIV cases, since not every 
infection is immediately diagnosed.16
The growing eﬀ ect of ART on the survival period from 
infection to death also challenges the other modelling 
approaches relying on HIV prevalence data to estimate 
trends in HIV incidence, including the UNAIDS approach.17 
Indeed, the connection between prevalence and 
incidence becomes weaker with increasing use of ART and 
the resulting increases in life expectancy of people living 
with HIV. Moreover, the way in which ART interferes with 
prevalence and incidence trends is dependent on many 
factors, such as level of access to ART, heterogeneity 
in access, timing of initiation, adherence and response 
to ART, and survival and HIV transmission on ART. The 
scarcity of high-quality, country-speciﬁ c data hampers 
adequate accounting for all these factors in these 
modelling approaches. Similar issues were encountered 
with the ﬁ rst generation of back-calculation methods, 
which relied on AIDS case reporting and could no longer 
be used after ART became available.18
Therefore, in a context with high or increasing access 
to ART, incidence estimates should focus neither on 
HIV mortality data nor on prevalence data. In many 
high-income countries, high-quality HIV surveillance 
systems exist based on case reporting of all new HIV 
diagnoses. These data are used to estimate country 
incidence on the basis of two main statistical approaches: 
extended back-calculation models of newly diagnosed 
HIV cases or biomarker approaches requiring data for 
recent infections.9,18 These methods can additionally 
be used to provide estimates at a subnational level to 
better characterise the epidemic and target adequate 
interventions.19 HIV surveillance systems collecting data for 
ART uptake exist in many low-income and middle-income 
countries. Although these data are currently underused, 
new extensions of the back-calculation approach could be 
developed to derive incidence estimates.
Continued production of timely and reliable data 
for HIV prevalence and mortality is important and, 
in that sense, the contributions of both UNAIDS and 
GBD are highly valuable. However, without timely and 
reliable assessment of HIV incidence, achievement of 
the 90-90-90 UNAIDS target and ending of the HIV 
epidemic will be challenging. It is time to make the right 
investments.20
Virginie Supervie, *Dominique Costagliola
Sorbonne Universités, UPMC Univ Paris 06, INSERM, Institut 
Pierre Louis d’Epidémiologie et de Santé Publique 
(IPLESP UMR_S 1136), F75013, Paris, France (VS, DC)
dominique.costagliola@iplesp.upmc.fr
DC was a member of the French Gilead HIV board up to 2015; has given lectures 
and done post-marketing studies for Janssen-Cilag, Merck-Sharp & 
Dohme-Chibret, and ViiV; has received travel, accommodation, or meeting 
expenses from Gilead, ViiV, Janssen-Cilag; and is currently a consultant of 
Innavirvax. VS declares no competing interests. VS thanks the National Agency 
of Research on AIDS and Viral Hepatitis for funding support.
Comment
www.thelancet.com/hiv   Vol 3   August 2016 e339
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access 
article under the CC BY license.
1 Wandeler G, Johnson LF, Egger M. Trends in life expectancy of HIV-positive 
adults on antiretroviral therapy across the globe: comparisons with general 
population. Curr Opin HIV AIDS 2016; published online May 31. 
DOI:10.1097/COH.0000000000000298.
2 Vermund SH, Hayes RJ. Combination Prevention: New Hope for Stopping 
the Epidemic. Curr HIV/AIDS Rep 2013; 10: 169–86.
3 Brookmeyer R. Measuring the HIV/AIDS epidemic: approaches and 
challenges. Epidemiol Rev 2010; 32: 26–37.
4 Hallett TB, Zaba B, Stover J, et al. Embracing diﬀ erent approaches to 
estimating HIV incidence, prevalence and mortality. AIDS 2014; 
28 (suppl 4): S523–32.
5 Murray CJ, Ortblad KF, Guinovart C, et al. Global, regional, and national 
incidence and mortality for HIV, tuberculosis, and malaria during 
1990-2013: a systematic analysis for the Global Burden of Disease Study 
2013. Lancet 2014; 384: 1005–70.
6 GBD 2015 HIV Collaborators. Estimates of global, regional, and national 
incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden 
of Disease Study 2015. Lancet HIV 2016; published online July 19. 
http://dx.doi.org/10.1016/S2352-3018(16)30087-X.
7 UNAIDS. Global AIDS update 2016. http://www.unaids.org/sites/default/ﬁ les/
media_asset/global-AIDS-update-2016_en.pdf (accessed June 20, 2016).
8 Wandel S, Egger M, Rangsin R, et al. Duration from seroconversion to 
eligibility for antiretroviral therapy and from ART eligibility to death in 
adult HIV-infected patients from low and middle-income countries: 
collaborative analysis of prospective studies. Sex Transm Infect 2008; 
84 (suppl 1): i31–36.
9 Supervie V, Archibald CP, Costagliola D, et al. GBD 2013 and HIV incidence 
in high income countries. Lancet 2015; 385: 1177.
10 European Centre for Disease Prevention and Control. HIV/AIDS surveillance 
in Europe 2014. http://ecdc.europa.eu/en/publications/Publications/hiv-
aids-surveillance-in-Europe-2014.pdf (accessed June 20, 2016).
11 Centers for Disease Control and Prevention. HIV surveillance report, 2014. 
http://www.cdc.gov/hiv/pdf/library/reports/surveillance/cdc-hiv-
surveillance-report-us.pdf (accessed June 20, 2016).
12 Public Health Agency of Canada. HIV and AIDS in Canada: surveillance 
report to December 31st, 2013. http://www.phac-aspc.gc.ca/aids-sida/
publication/survreport/2013/dec/index-eng.php (accessed June 20, 2016).
13 The Kirby Institute. HIV, viral hepatitis and sexually transmissible infections 
in Australia. Annual surveillance report 2015. Available at http://kirby.
unsw.edu.au/sites/default/ﬁ les/hiv/resources/ASR2015_v4.pdf (accessed 
June 20, 2016).
14 InVS. Découvertes de séropositivité VIH et de sida. Point épidémiologique 
du 1er avril 2016. http://www.invs.sante.fr/Dossiers-thematiques/
Maladies-infectieuses/VIH-sida-IST/Infection-a-VIH-et-sida/Actualites/
Decouvertes-de-seropositivite-VIH-et-de-sida.-Point-epidemiologique-du-
1er-avril-2016 (accessed June 20, 2016).
15 Country Coordinating Mechanism Russia. The ﬁ ght against HIV/AIDS and 
tuberculosis: Country Coordinating Mechanism in action. http://www.
hivrussia.ru/skm/info_en.shtml (accessed June 20, 2016).
16 Mocroft A, Lundgren J, Antinori A, et al. Late presentation for HIV care 
across Europe: update from the Collaboration of Observational HIV 
Epidemiological Research Europe (COHERE) study, 2010 to 2013. 
Euro Surveill 2015; published online Nov 18. DOI:10.2807/1560-7917.
ES.2015.20.47.30070.
17 Hallett TB. Estimating the HIV incidence rate: recent and future 
developments. Curr Opin HIV AIDS 2011; 6: 102–07.
18 Working Group on Estimation of HIV Prevalence in Europe. HIV in hiding: 
methods and data requirements for the estimation of the number of 
people living with undiagnosed HIV. AIDS 2011; 25: 1017–23.
19 Marty L, Cazein F, Pillonel J et al. Mapping the HIV epidemic to improve 
prevention and care: the case of France. 21st International AIDS 
Conference; Durban, South Africa; July 18–22, 2016. TUAC0203 (abstr).
20 Boerma JT, Stansﬁ eld SK. Health statistics now: are we making the right 
investments? Lancet 2007; 369: 779–86.
Geographical mobility and heterogeneity of the HIV epidemic
Improved HIV surveillance, novel and creative data 
sources and data collection technologies, and long-term 
cohort studies help to identify ﬁ ne-scale geographical 
heterogeneities in HIV prevalence and incidence. In 
The Lancet HIV, Larry Chang and colleagues1 document 
substantial heterogeneities using a population-based 
cohort study to assess HIV disease burden, sexual 
behaviours, and treatment and prevention service 
coverage in Rakai, Uganda. They mapped HIV prevalence 
and assessed diﬀ erences in HIV risk factors and uptake 
of antiretroviral therapy and male circumcision among 
people in agrarian (n=9931), trading (n=3318), and 
ﬁ shing (n=3870) communities. HIV prevalence ranged 
from 9% to 43%, with the highest prevalence in 
Lake Victoria ﬁ shing communities.
This persistence of heterogeneity in HIV prevalence 
four decades since HIV/AIDS emerged in Uganda across 
communities even within a small geographical area is 
remarkable. The message is clear: geography aﬀ ects 
risk. How and why HIV risk can change so quickly 
over space and time is less clear, but is probably a 
result of patterns of human geographical mobility 
and contextual factors in addition to individual 
behaviours. To understand and respond to ﬁ ne-scale 
heterogeneities, we must consider the social and 
cultural contexts in which HIV continues to circulate. 
Rigorous social science theory and research need to 
be integrated into all stages of the scientiﬁ c process, 
from descriptive epidemiological studies to planning, 
targeting, and implementing HIV prevention eﬀ orts in 
transmission hotspots and most-at-risk populations.2,3 
In the case of African inland ﬁ shing communities, and 
indeed in most other settings where HIV prevalence 
is high, we must understand sex-speciﬁ c patterns of 
mobility and HIV risk to respond to the epidemic. 
The focus of mobility as a factor in risk, spatial diﬀ usion, 
and transmission dynamics of HIV has changed markedly 
since the early days of research on male truck drivers.4,5 
Increasingly, a thorough understanding of how and 
why mobility patterns are intertwined with HIV risk and 
transmission patterns over time and space is emerging 
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